The Swiss pharma giant intends to nearly double its operational footprint in the state to more than 700,000 square feet between the existing campus and new facilities.
Expansion at the facility will roll out in phases and position the South Korea–based biosimilars manufacturer to build an integrated U.S. manufacturing supply chain.
